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The diastereoisomeric dichlore[ 1-(2-, 3- and 4-hydmxyphenyl)-2-phenyl- 
ethylenediamine]platinum(Il) complexes were tested on two human ovarian 
cancer cell lines NIH OVCAR-3 and SK-OV-3, both resistant against cis- 
platin Dichloro-[fhreo-1-(3-hydroxyphenyl)-2-p~nylethyle~iami~]plati- 
num(II) (rhreo-S-PtC12) proved to be the most active representative of the 
new series, producing cytocidal effects at a concentration range of 2.5 to 5.0 
pM on the NM: OVCAR-3 cell Line. On the more resistant SK-OV-3 cell 
line, threo-5-PtC12 was only moderately active, while in combination with 
BSO, a GSH level lowering compound, fhreo-5-PtC12 showed a strong syn- 
ergistic effect. 
Dichlor~[l-(hydroxyphenyl)-2phenylethylendlamin]piatin(II)-Kom- 
plexe. m n g  an den mensehllchen Ovarialcarclnom-Zellinlen NIH: 
OVCAR-3 und SK-OV-3 
Die diastereomeren Dichloro-[ 1-(2-, 3- und 4-hydroxyphenyl)-2-phenyleth- 
ylendiamin]platin(lI)-Komplexe wurden an zwei cisplatinresistenten, 
menschlichen Ovarialcarcinom-Zellinien, NIH: OVCAR-3 und SK-OV-3, 
getestet. Dichloro-[rhreo-l-(3-hydroxyphenyl)-2-phenylethylendi~in]p~a- 
tin(II) (threo-J-PtCl2) envies sich als der aktivste Vertreter der Reihe. Threo- 
5-PtC12 ~ f i  im Konzentrationsbereich 2.5 - 5.0 an der NM: OVCAR-3 
Zellinie cytocide Effekte hervor. An der resistenten SK-OV-3 Zellinie war 
rhreo-S-PtC12 nur d i g  wirksam; es zeigte aber in Kombination mit BSO. 
einer GSH-Spiegel emiedrigenden Substanz. stark synergistische Effekte. 
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X‘ In recent publicationsi4) we have shown that stereoisomeric dichloro- 
4-OH (1,2-diphenylethylenediamine)platinurn(II) complexes with hydroxy 
2-OH groups in the 4-,3- or 2-positions of both benzene rings (Scheme 1, com- 
H pounds 1-PtC12 to 3-PtCld are of interest as antitumor agents. D,L-&PtCI2 
ent Ehrlich ascites tumor of the mouse. In this experiment 70% of the 
tumor-bearing animals were cured by complex D,L-%Ptc12 but only 20% 
by complex meso-3-PtC12). 
This result prompted us to a thorough study of the stereo- 
isomeric [ 1,2-bis(2-hydroxyphenyl)ethylenediamine]dichlo- 
roplatinum(II) complexes (meso-, D,L-, (+)-, and (-)-3- 
PtC12) on the NIH : OVCAR-3 ovarian cancer cell line, 
which exhibits a multidrug resistance phenotype (compare 
ref?) and footnote 1). The NIH : OVCAR 3 cell line was 
established from a patient with ovarian cancer who was 
treated unsuccessfully with cisplatin, adriamycin and cyclo- 
phosphamide’! Among the studied stereoisomeric 3-PtC12 
complexes the (S),(S)configurated, levorotatory compound 
proved to be the most active one. Since non-toxic concen- 
trations of this compound produces cytocidal effects on the 
NIH: OVCAR 3 cell line, it is of interest for further evalu- 
ation for the therapy of ovarian cancer. 
This publication will report on the testing of the structu- 
rally related diastereomeric dichloro-[ 1-(hydroxypheny1)-2- 
3-OH 
H 
H and especially ~,~.-3-Ptc12 led to a marked inhibition of the cisplatin-resist- 
1. Cisplatin based combination chemotherapy regimens produce complete remissions in 6040% of patients with advanced stage ovarian cancer. However, 
their effectiveness is limited by the development of acquired resistance”. Therefore, the development of new platinum complexes, which overcome the 
cisplatin resistance, is of great interest: (a) in combination with cisplatin for first-line treatment of ovarian cancer to avoid or retard the development to 
resistance. (b) for the second-line therapy of ovarian cancer after development of resistance against cisplatin. 
= Dedicated to Professor Dr. Dr. E. Mutschler on the occasion of his 60th birthday. 
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phenylethylenediamine]platinum(II) complexes on the 
human epithelial ovarian cancer cell lines NIH: OVCAR-3 
Derivatives which are OH-substituted in 2-, 3-, and 4-PO- 
sition (4-PtC12, 5-PtCl2, and 6-PtC12; Scheme 1) were used 
in this study. With the exception of eryrhro-4-PtCl2, the 
synthesis which was not successful (cf. ref?)), all com- 
pounds were available as threo- and erythro-forms. 
For characterization of both cell lines a cytogenetic ana- 
lysis as well as an investigation of growth kinetics and of 
the sensitivity against the therapeutically most used drug 
cisplatin were performed. 
The cytogenetic analysis demonstrated that the NIH: 
OVCAR-3 cell line included cells with a hypotriploid to a 
hypohexaploid karyotype and the SK-OV-3 cells with a hy- 
podiploid to a hypotetraploid karyotype. The modal chro- 
and SK-OV-3. 
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mosome numbers amount to 63 for NIH: OVCAR-3 (Fig. 1) 
and to 43 and 83 for SK-OV-3 (Fig. 2). The karyograms of 
both cell lines show numerous chromosome anomalies. 
Their morphological and cytogenetic characteristic proved 
to be constant in the course of the study. 
Fig. 3A and B illustrate examplarily the growth curves 
and the corresponding doubling times at any time of incuba- 
tion for the MH: OVCAR-3 cell line in the passages 30 and 
32 (see footnote 2)). Under the given experimental condi- 
tions the logarithmic phase covers only a small fraction of 
the overall growth curve. In a plot doubling time versus 
time of incubation exponential growth is characterized by a 
parallelism of the graphs with the X-axis. The NIH: 
OVCAR-3 cell line grows exponentially for about two 
generations. The same is true for the SK-OV-3 cell line in 
the passages 38 to 40, which were used for the evaluation of 
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Fig. 1: Chromosome distribution of NIH-OVCAR 3 cells. (0) 29th passage 
from origin, (m) 51th passage from origin: The cells were passaged weekly. 
For each passage the chromosomes from 50 well-spread metaphase plates 
were counted. counted. 
Fig. 2: Chromosome distribution of SK-OV-3 cells, (0) 32th passage from 
origin, (B) 42th passage from origin: The cells were passaged weekly. For 
each passage the chromosomes from 50 well-spread metaphase plates were 
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Fig. 3: Growth curves and corre- 
sponding doubling times of the 
NIH OVCAR-3 cell line in de- 
pendence on the passage number. 
Inoculum: 100 pl/well at a density 
of 19,25 cells/microscopic field for 
0 100 200 300 h passages 30,32. 
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Fig. 4B: Variation of time of drug exposure: Effect of cisplatin (A: 1 pM) 
on the proliferation of NIH: OVCAR-3 ovarian cancer cells. Plot of correc- 
ted T/C values versus time; Inoculum: 100 pvwell at a density of 17 cells 
(37th passage)/microscopic field; preincubation 61 h; drug incubation 1.3.6, 
and 12 h; final incubation without drug; duration of the experiment 244 h. 
Fig. 4 A  Effect of cisplatin on the proliferation of NIH: OVCAR-3 ovarian 
cancer cells. Plot of corrected T/C values versus time of drug exposure. 
Inoculum: 100 pVwell at a density of 19 cells (30th passage) / microscopic 
field; preincubation 73.5 h, drug incubation 256 h. 
the antitumor activity of the new platinum complexes. A 
doubling time of about 35 h was estimated for the NIH. 
OVCAR-3 line and one of about 28 h for the SK-OV-3 line. 
In order to get informations on the sensitivity of the NIH: 
OVCAR-3 cell line against cisplatin, the most active drug in 
the therapy of ovarian cancer, the cells were incubated with 
this compound at therapeutically relevant concentrations for 
256 h. Only at the highest concentrations (1 and 5 mM) a 
cytocidal effect, which we consider essential for a curative 
effect in vivo, could be detected (Fig. 4A). However, a rela- 
tively long period of contact between cells and cisplatin (6 h) 
is required to achieve cell kill (compare Fig. 4B). Due to the 
marked toxic side effects and the pharmacokinetics of cis- 
platin it is difficult to meet this demand. The SK-OV-3 
ovarian cancer cell line proved to be less sensitive against 
cisplatin than the NIH: OVCAR-3 line (Fig. 5). In a concen- 
tration of 2.5 pM, which produced cytocidal effects on the 
NIH: OVCAR-3 cell line, cisplatin showed merely cyto- 
static activity on the SK-OV-3 cell line. After an incubation 
period of about 140 h development of resistance of the SK- 
OV-3 cells occurred. 
In long term experiments (256 h drug incubation) the dia- 
stereoisomeric dichloro-[ l -(hydroxyphenyl)-2-phenylethy- 
lenediamine]platinum(II) complexes showed a strong con- 
centrationdependent activity on the cisplatin-resistant NIH: 
OVCAR-3 cell line (Fig. 6-10). 
In the threo series the 2- and 3-hydroxy-substituted com- 
plexes (threo-CPtC12 and fhreo-5-PtCl2) produced cytocidal 
effects at a concentration of 5 pM (Fig. 6 and 7). The 4-hy- 
droxy-substituted complex (threo-CPtCl2) was merely cy- 
tostatically active at this concentration (5 pM, Fig. 9). Com- 
parison of the activity of fhreu-rl-PtC12 and threo-5-PtCl2 at 
lower concentrations reveals the superiority of rhreo-5-PtCl~. 
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Fig. 5: Effect of cisplatin on the proliferation of SK-OV-3 ovarian cancer 
cells. Plot of corrected T/C values versus time of drug exposure. Inoculum: 
100 pl/well at a density of 7 cells (38th passage) / microscopic field; 
preincubation 77 h, drug incubation 162 h. 
Erythro-5-PtCl2, which also brought about cytocidal effects 
at the highest concentration (5 pM), was less active than its 
diastereoisomer rhre0-5-PtQ (compare Fig. 7 and 8). The 
antitumor activity of eryrhro-5-PtCl2 was comparable with 
that of threo-CPtCl2. In contrast to the diastereoisomeric pair 
5-PtCl2 (threo-Ei-PtClz is more active than erythro-5-PtC12) 
the eryrhro-6-PtQ proved to be somewhat more active than 
its counterpart thre0-6-PtQ (compare Fig. 9 and 10). The 
comparison of the test results of rhreo-5-PtC1.2, the most ac- 
tive representative of the new series, with those of (-)-3- 
2. Comparable growth kinetics were also observed for the higher passage numbers of the NIH: OVCAR-3 cell line which were used in the test series. 
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Fig. 6-11: Effect of rhreo-4-PtCI2, threo-S-F'tCI2, eryrhro-5-PtCI2. rhreOaPtCl2, erythro-6-PtCIz, and (-)-3-W12 on the proliferation of NIH OVCAR-3 
ovarian cancer cells. Plot of corrected T/C values versus time of drug exposure. Inoculum: 100 pVwell at a density of 19 cells (30th passage) /microscopic 
field; preincubation 73.5 h; drug incubation 265 h. 
PtC12, which we used as positive control, showed a higher 
potency of the latter (compare Fig. 7 and 11). 
To find out the time which is necessary to achieve a cyto- 
cidal effect of threo-5-PtCl2, the most active representative 
of the new platinum complexes, the NIH: OVCAR-3 cells 
were preincubated with this drug at concentrations of 2.5 
and 5.0 pM for 1, 3, 6, and 12 h, respectively, and the 
growth curves were registered after removal of the drug by 
medium exchange (duration of the experiment 244 h). In a 
concentration of 5.0 pM rhreo-S-PtCl2 produced cytocidal 
effects after a drug-cell-contact of at least 3 h (Fig. 12A). 
However, at a concentration of 2.5 pLM only a drug incuba- 
tion time of 12 h led to cytocidal effects (Fig. 12B). 
Comparative experiments with (-)-3-PtC12 (which was used 
as control) revealed that at a drug concentration of 2.5 pM in- 
cubation times of 2 3 h were necessary to bring about cyto- 
cidal effects (Fig. 13). From this experiment, too, the supe- 
riority of (-)-3-PtC12 compared with rhreo-5-PtC12 becomes 
evident. 
On the SK-OV-3 ovarian cancer cell line, which showed a 
marked resistance against cisplatin, only the most active 
representative of the new series, rhreo-S-PtClz was testet. 
Even at the highest concentration (5 pM) only a weak cy- 
tostatic effect was obvious (Fig. 14). The comparison com- 
pound (-)-3-PtC12 displayed a similar low activity, which 
was even limited in time. After a drug incubation of 150 h. 
cells grow unlimited (Fig. 15). 
In the development of the resistance of ovarian cancer against cisplatin 
the ability of malignant cells to elevate its content of glutathione (GSH) is 
supposed to be of great importance5'. Glutathione inactivates drugs like cis- 
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Fig. 13: Variation of the time of drug exposure: Effect of (-)-3-PtC12 (2.5 
pM) on the proliferation of NIH: OVCAR-3 ovarian cancer cells. Plot of 
corrected T/C values versus time; Inoculum: 100 pl/well at a density of 17 
cells (37th passage)/microscopic field; preincubation 61 h; drug incubation 
1,3,6, and 12 h; final incubation without drug: duration of the experiment 
244 h. 
platin, which produce their effect by reaction with nucleophilic targets of the 
tumor cell (e.g. DNA). Therefore, drugs causing a GSH reduction in the 
cells should lead to a potentiation of the effect of platinum complexes. In 
this context buthionine sulfoximine (BSO), an inhibitor of the y-gluta- 
mylcsteine synthetase, the key enzyme of GSH biosynthesis. has met great 
interest. At a concentration range of 15 to 25 pM it produces areduction of 
the GSH level of about 85% in N I H  OVCAR-3 cells and, as a consequence, 
markedly elevates the inhibitory effect of cisplatin on this cell line5’. 
Due to these findings the combined administration of BSO 
and platinum complexes is being thoroughly studied. Our 
experiments on the SK-OV-3 cell line revealed a strong 
effect of fhreo-5-PtClz in a concentration of 2.5 pM after 
preincubation with BSO (50 pM, 48 h; Fig. 17). 
This is a remarkable finding, since both substances, rhree 
5-PtC12 (2.5 pM) and BSO (50 pM) are ineffective when 
Fig. 12: Variation of the time of drug expo- 
sure: Effect of rhreo-IPtClz (A. 2.5 pM: B: 
5.0 pM) on the proliferation of NIH. OV- 
CAR-3 ovarian cancer cells. Plot of correc- 
ted T/C values versus time. Inoculum: 100 
@/well at a density of 17 cells (37th passa- 
ge) / microscopic field, preincubation 61 h; 
drug incubation 1,3,6, and 12 h; final incu- 
bation without drug: duration of the experi- 
1 0 0  200 300 h ment244h. 
applied singly (compare Fig. 14 and 16). (-)-3-PtC12 was 
markedly less active under the same conditions (Fig. 18). It 
causes only weak cytostatic effects. 
Also with cisplatin, the antitumor effect was only slightly 
increased by BSO. At the therapeutically relevant cisplatin 
concentration (0.5 pM) a combination with BSO (50 pM) 
gave no cytocidal effects. 
Only at therapeutically non-relevant cisplatin concentra- 
tions (2.5 yM), which are themselves markedly cytostatic, 
the additional treatment with BSO ends up in a vast cell kill 
(Fig. 19). The strongly synergistic effect of the fhreo-5- 
PtClflSO combination could be of great interest in the 
therapy of the cisplatin resistent ovarian cancer. 
Further investigations using in vifro and in vivo ovarian 
cancer models are planned. 
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Biological methods 
NIH : OVCAR-3 ovarian cancer cell line. The NIH 
OVCAR-3 (ATCC no. HTB 161), a human adenocarcinoma 
of the ovary’), was obtained from the American Type Culture 
Collection in passage 17. Cell-line-banking and quality con- 
trol were performed according to the “see stock concept“ re- 
viewed by Hay’’. The cells were maintained in RPMI-1640 
(Sigma) containing NaHC03 (2 gfl), gentamicin (50 ma), 
10% BMS (Seromed) and insulin (10 yglml) (Sigma) in 75- 
cmz flasks at 37°C in a H,O-saturated atmosphere of 95% air 
and 5% COz. The cells were serially passaged weekly fol- 
lowing trypsinization using trypsin/EDTA (Boehringer). For 
chemosensitivity testing the cells (in passage 24,30,32,37, 
and 49, respectively, were plated in 96-well microplates (100 
pl/well at a density of about 17-28 cells/microscopic field 
(Leitz Diavert, 320x)) and were allowed to attach. After 48- 
80 h, the medium was removed by suction and replaced with 
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Fig. 14 and 15: Effect of rhreo-5-PtClz and (-)-3-PtC12 on the proliferation of SK-OV-3 ovarian cancer cells. Plot of corrected 
T/C values versus time of drug exposure. Inoculum: 100 hl/well at a density of 7 cells (38th passage) / microscopic field; 
preincubation 77 h drug incubation 162 h. 
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Fig. 1 6  Effect of BSO (30 and 60 pM) on the proliferation of SK-OV-3 
ovarian cancer cells. Plot of corrected T/C values versus time of drug expo- 
sure. Inoculum: 100 pl/well at a density of 100 cells (39th passage) / mi- 
croscopic field preincubation 44 h, drug incubation 160 h. 
fresh medium (200 kl/well) containing drug (drugs were 
added as a 1000-fold stock solution) or pure solvent. The 
platinum complexes were dissolved in DMF. On every plate 
two rows (n = 16) acted as controls, whereas two vertical 
rows (n = 16) per drug concentration and time point were 
used. After various times of incubation the cells were fixed 
with glutaraldehyde and stored under PBS at 4OC. All plates 
were stained with crystal violet simultaneously. The process- 
ing procedure and data analysis were performed as described 
by Reile et a1.l'). Drug effects were calculated as corrected 
T/C values according to: T/C,, = (T - C&(C - Co) 100 [%I, 
where T is the absorbance of treated cells, C the absorbance 
of the controls and C, the absorbance at the time (t = 0) when 
drug was added. The experimental errors for T/C,, range 
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Fig. 17: Effect of rheo-5-PtC12 (2.5 pM) on the proliferation of SK-OV-3 
ovarian cancer cells after preincubation with BSO (50 pM, 48 h). Plot of 
corrected T/C values versus time. Inoculum: 100 pl/well at a density of 10 
cells (39th passage) / microscopic field; preincubation without drugs 44 h: 
duration of the experiment 120 h. 
from approximately f 20% after short times of incubation 
(small values for T and C compared to G) to It 5% with pro- 
longed incubation. 
SK-OV-3 ovarian cancer cell line. The experiment with 
the SK-OV-3 cell line (ATCC no. HTB 77)'') were per- 
formed in the same manner as with NIH: OVCAR-3. Con- 
trary to this procedure cells in passage 38 were plated at a 
density of about 7 cells/microscopic field (Leitz Diavert, 
320x) for chemosensitivity testing. After 77 h the medium 
was replaced by fresh medium containing drug or pure sol- 
vent (control). 
Cyrogenetic analysis. The cells were grown to about 50% 
confluence on microscopic slides. The slides were prepared 
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Fig. 18 and 19: Effect of (-)-3-PtCI2 (2.5 pM) and cisplatin (2.5 pM) on the proliferation of SK-OV-3 ovarian cancer cells after 
preincubation with BSO (50 pM, 48 h). Plot of corrected T/C values versus time of drug exposure. Inoculum: 100 pUwell at a 
density of 10 cells (39th passage) / microscopic field; preincubation without drugs 44 h: duration of the experiment 120 h. 
as described”’. So that spindle formation could be inhibited, 
the slide chambers were inoculated with colcemid solution 
(Serva) to a final concentration of 0.04 pgml and incubated 
for 3 h at 37OC. The medium was removed by suction and 
replaced with 0.075 M KC1. After 30 min of incubation at 
37°C an equal volume of cold, freshly made fixative (absol. 
methanol/glacial acetic acid, 3/1) was added. This hypo- 
tonic/fixative mixture was removed immediately and re- 
placed twice by ice-cold, fresh fixative. The slides were 
removed from the dish and air-dried at 6OOC. The chromo- 
somes were stained for 8 min with 10 ml Giemsa plus 90 ml 
of 0.025 M KH,PO,, pH 6.8. 
Doubling rime analysis. Curve fitting of experimental data 
of the growth curves is accomplished by a polynomal re- 
gression fit applying the least-squares method”). 
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